Quick Answer
TAKEDA PHARMACEUTICAL CO LTD reported R&D Expense of $730.23 billion for fiscal year 2025.
TAKEDA PHARMACEUTICAL CO LTD R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $730.23B | +0.0% |
| 2024 | $729.92B | +15.3% |
| 2023 | $633.33B | +20.4% |
| 2022 | $526.09B | +15.4% |
| 2021 | $455.83B | -7.4% |
| 2020 | $492.38B | +33.7% |
| 2019 | $368.30B | +13.2% |
| 2018 | $325.44B | +4.2% |
| 2017 | $312.30B | — |
- TAKEDA PHARMACEUTICAL CO LTD showed an increase of +0.0% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, TAKEDA PHARMACEUTICAL CO LTD’s r&d expense has grown by 133.8% (from $312.30 billion to $730.23 billion).
- The most recent figure is from TAKEDA PHARMACEUTICAL CO LTD’s fiscal year 2024 report (Form 20-F), filed with the SEC on June 25, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: